Company
Drug candidate
Indication
AFFiRiS AG
AD01 AD03 PD01 ATH03
Alzheimer’s disease Alzheimer’s disease Parkinson’s disease Atherosclerosis
Akron Molecules GmbH
AKR 203
Pain
F-star Biotechnologische Forschungs- und Entwicklungs GmbH
FS102
Solid Tumors
Life Research Technologies GmbH
PROCURE
Ovarian Epithelial Cancer
NABRIVA Therapeutics AG
BC-7013
Uncomplicated skin and skin structure infections (uSSSI)
PDC Biotech GmbH
PDC31
Primary dysmenorrhea
Recardio GmbH
REC-01 REC-02
Acute myocardial infarction Congestive heart failure
Themis Bioscience GmbH
Vaccine
Chikungunya
Valneva Austria GmbH
EB66 vacc.
Influenza
Activartis Biotech GmbH
AV0113
Glioblastoma multiforme (GBM)
AFFiRiS AG
AD04
Alzheimer’s disease
Akron Molecules GmbH
AKR 202
Pain (Osteoarthritis)
APEIRON Biologics AG
APN01 APN301
Acute Respiratory Distress Syndrome (ARDS) Neoplastoma
APEPTICO Forschung und Entwicklung GmbH
AP301
Acute lung injury
Biomay AG
BM32
Grass Pollen Allergy
F4 Pharma i.G.
FX06
Hemorrhage
Innovacell Biotechnologie AG
ICEF15
Incontinence
NABRIVA Therapeutics AG
BC-3781
Bacterial infections
Valneva Austria GmbH
IC31 VLA84
Adjuvant tuberculosis Clostridium difficile vaccine
Vivaldi Biosciences GmbH
Vaccine
Influenza
Zytoprotec GmbH
PD-protec™
Peritoneal Dialysis
Innovacell Biotechnologie AG
ICES13
Stress urinary incontinence
Valneva Austria GmbH
VLA43
Pseudomonas aeruginosa
APN311
High-risk neuroblastoma
Phase I
Phase II
Phase III
Approval Process APEIRON Biologics AG
Table 4: Drug candidates of dedicated biotechnology companies in clinical phase I till approval process in 2014
17
2-1-0_LSR-Austria_2015_Dedicated-Biotech-Companies.indd 17
16.09.2015 14:37:51 Uhr